BVS Bioventus Inc.
Data as of close
Healthcare · Surgical & Medical Instruments & Apparatus
Bioventus Inc. (BVS) is a healthcare company in the Surgical & Medical Instruments & Apparatus industry, with a market capitalization of $731 million. Shares last traded at $10.67, 32.8% below their 52-week high. Over the past year the stock is up 41.7%. BVS trades at a price-to-earnings ratio of 12.75, below the Surgical & Medical Instruments & Apparatus median of 30.84. Net profit margin is 9.8%, above the peer median of -6.2%. Revenue declined 0.9% year over year.
* P/E (TTM) = market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year — the same basis as the peer table and the screener, so it can differ from price ÷ EPS.
Performance
Chart
Full chart →Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.
Technicals
Financials
Trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year; revenue is the fiscal-year figure where quarterly revenue covers under half of it (typical for banks, insurers and REITs), and margins are taken on it; latest reported period ends 2026-09-26. Source: SEC EDGAR/XBRL.
Recent earnings
| Period | EPS (diluted) | Reported |
|---|---|---|
| Q3 2026 | $0.08 | 2026-11-02 |
| Q2 2026 | $0.47 | 2026-08-05 |
| Q1 2026 | $0.04 | 2026-05-06 |
| Q4 2025 (derived) | $0.21 | 2026-03-05 |
| FY 2025 | $0.33 | 2026-03-05 |
| Q3 2025 | $0.05 | 2025-11-04 |
Q4 marked "derived" = fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive, so it can differ by a cent or two from the issuer's own Q4.
Surgical & Medical Instruments & Apparatus peers
BVS vs 14 industry peers (Surgical & Medical Instruments & Apparatus), by market cap. Data as of close
| SYK | Stryker Corporation | $127.6B | 35.21 | 4.85 | 13.8% | -1.37% |
| MMM | 3M | $97.0B | 27.44 | 3.84 | 14.0% | -3.21% |
| BSX | Boston Scientific | $64.7B | 18.51 | 3.07 | 16.6% | -2.60% |
| BDX | Becton Dickinson | $58.2B | 61.80 | 2.79 | 4.5% | +2.10% |
| MDLN | Medline Inc. | $34.9B | — | 1.23 | 4.1% | -1.55% |
| RMD | ResMed | $33.7B | 21.13 | 5.87 | 27.8% | -0.48% |
| DXCM | DexCom | $31.5B | 31.79 | 6.17 | 19.4% | -4.53% |
| WST | West Pharmaceutical Services | $27.3B | 42.78 | 8.05 | 18.8% | -4.03% |
| SOLV | Solventum | $14.8B | 94.78 | 1.81 | 1.9% | -2.50% |
| BAX | Baxter International | $13.3B | — | 1.14 | -6.2% | -3.28% |
| GKOS | Glaukos Corp | $13.0B | — | 18.87 | -24.6% | -10.74% |
| PEN | Penumbra Inc | $12.7B | 80.64 | 9.02 | 12.7% | -0.39% |
| PODD | Insulet Corporation | $10.8B | 25.26 | 3.40 | 13.4% | -5.35% |
| GMED | Globus Medical Inc | $10.8B | 19.34 | 3.43 | 17.8% | -6.53% |
Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.